InsiderTrades

Form 4 for ACRS Aclaris Therapeutics, Inc.

Accepted 2023-03-03 00:00:00 ET · period of report 2023-03-01 · accession 0001209191-23-016065 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2023-03-03 2023-03-01+ ACRS Monahan Joseph CSO M - OptEx — +87.2K 166.1K +111% —
DM 2023-03-03 2023-03-02+ ACRS Monahan Joseph CSO S - Sale+OE $12.51 -30.8K 147.7K -17% -$385.6K
DM 2023-03-03 2023-03-01+ ACRS Monahan Joseph CSO M - OptEx $0.00 -87.2K 12.5K -87% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-03-01 M A 50,000 — 155,136 D — — (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
2 Common Common Stock 2023-03-02 M A 12,500 — 163,761 D — — (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
3 Common Common Stock 2023-03-02 S D 14,800 $12.37 151,261 D — — (F3) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.90 to $12.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4 Common Common Stock 2023-03-01 M A 13,750 — 105,136 D — — (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
5 Common Common Stock 2023-03-03 S D 16,037 $12.63 147,724 D — — (F5) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.43 to $12.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6 Common Common Stock 2023-03-01 M A 10,925 — 166,061 D — — (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
7 Derivative Restricted Stock Units 2023-03-01 M D 13,750 $0.00 0 D — · — to — 13,750 Common Stock (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F6) The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
8 Derivative Restricted Stock Units 2023-03-01 M D 50,000 $0.00 100,000 D — · — to — 50,000 Common Stock (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F7) The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
9 Derivative Restricted Stock Units 2023-03-01 M D 10,925 $0.00 32,775 D — · — to — 10,925 Common Stock (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F8) The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.
10 Derivative Restricted Stock Units 2023-03-02 M D 12,500 $0.00 12,500 D — · — to — 12,500 Common Stock (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F9) The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.